AtheroGenics (AGIX) April option implied volatility Elevated into Trial Data
More News related to AGIX
- AtheroGenics (AGIX) Receives Delisting Notification From NASDAQ
- AtheroGenics Receives Notice of Non-Compliance With Listing Requirement for the NASDAQ Global Market
- BeaconEquity.com Issues TraderNotes on Stocks: TPIM, NSM, BRLC, AGIX, AROX, TLEO, HLYS, ABAT
- Fifteen New Alternative Energy Stocks Added - Four Stocks Deleted from Ardour Global Index in Quarterly Rebalancing
- AtheroGenics Reports Clinical Data on Novel Anti-Inflammatory Anti-Oxidant Agent, AGI-1067, at American Diabetes Association Annual Meeting
AtheroGenics (Nasdaq: AGIX) : AGIX focuses on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases. Top line data from the ARISE Phase 3 trial on AGI-1067 is expected in late winter/early spring of 2007. AGIX January option implied volatility is at 130, April is at 207 according to Track Data, suggesting larger price fluctuations are expected in early 2007. Paul Foster
Related Categories
FDAOptions
Stocks Mentioned
+0.05Sign up for StreetInsider Free!
Recieve full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
